124 related articles for article (PubMed ID: 22840611)
1. Cerebrospinal fluid levels of glutamate and corticotropin releasing hormone in major depression before and after treatment.
Garakani A; Martinez JM; Yehuda R; Gorman JM
J Affect Disord; 2013 Apr; 146(2):262-5. PubMed ID: 22840611
[TBL] [Abstract][Full Text] [Related]
2. Abnormality in glutamine-glutamate cycle in the cerebrospinal fluid of cognitively intact elderly individuals with major depressive disorder: a 3-year follow-up study.
Hashimoto K; Bruno D; Nierenberg J; Marmar CR; Zetterberg H; Blennow K; Pomara N
Transl Psychiatry; 2016 Mar; 6(3):e744. PubMed ID: 26926880
[TBL] [Abstract][Full Text] [Related]
3. CSF corticotropin-releasing hormone and somatostatin in major depression: response to antidepressant treatment and relapse.
Banki CM; Karmacsi L; Bissette G; Nemeroff CB
Eur Neuropsychopharmacol; 1992 Jun; 2(2):107-13. PubMed ID: 1352999
[TBL] [Abstract][Full Text] [Related]
4. Association analysis for corticotropin releasing hormone polymorphisms with the risk of major depressive disorder and the response to antidepressants.
Chang HS; Won E; Lee HY; Ham BJ; Lee MS
Behav Brain Res; 2015 Oct; 292():116-24. PubMed ID: 26055202
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid concentrations of corticotropin-releasing hormone, vasopressin, and somatostatin in depressed patients and healthy controls: response to amitriptyline treatment.
Heuser I; Bissette G; Dettling M; Schweiger U; Gotthardt U; Schmider J; Lammers CH; Nemeroff CB; Holsboer F
Depress Anxiety; 1998; 8(2):71-9. PubMed ID: 9784981
[TBL] [Abstract][Full Text] [Related]
6. Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with S-citalopram concentrations in plasma and cerebrospinal fluid (CSF) and clinical response.
Nikisch G; Mathé AA; Czernik A; Thiele J; Bohner J; Eap CB; Agren H; Baumann P
Psychopharmacology (Berl); 2005 Oct; 181(4):751-60. PubMed ID: 15988572
[TBL] [Abstract][Full Text] [Related]
7. Poor evidence for putative abnormalities in cerebrospinal fluid neurotransmitters in patients with depression versus healthy non-psychiatric individuals: A systematic review and meta-analyses of 23 studies.
Pech J; Forman J; Kessing LV; Knorr U
J Affect Disord; 2018 Nov; 240():6-16. PubMed ID: 30041075
[TBL] [Abstract][Full Text] [Related]
8. A follow up study of suicide attempters: increase of CSF-somatostatin but no change in CSF-CRH.
Westrin A; Ekman R; Regnéll G; Träskman-Bendz L
Eur Neuropsychopharmacol; 2001 Apr; 11(2):135-43. PubMed ID: 11313159
[TBL] [Abstract][Full Text] [Related]
9. Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression - a potential biomarker?
Ising M; Horstmann S; Kloiber S; Lucae S; Binder EB; Kern N; Künzel HE; Pfennig A; Uhr M; Holsboer F
Biol Psychiatry; 2007 Jul; 62(1):47-54. PubMed ID: 17123470
[TBL] [Abstract][Full Text] [Related]
10. Combined dexamethasone suppression-corticotrophin-releasing hormone stimulation test in medication-free major depression and healthy volunteers.
Sher L; Oquendo MA; Burke AK; Cooper TB; Mann JJ
J Affect Disord; 2013 Dec; 151(3):1108-12. PubMed ID: 23866302
[TBL] [Abstract][Full Text] [Related]
11. Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study.
Zisook S; Lesser IM; Lebowitz B; Rush AJ; Kallenberg G; Wisniewski SR; Nierenberg AA; Fava M; Luther JF; Morris DW; Trivedi MH
J Clin Psychiatry; 2011 Oct; 72(10):1322-32. PubMed ID: 22075098
[TBL] [Abstract][Full Text] [Related]
12. Effects of trauma-related audiovisual stimulation on cerebrospinal fluid norepinephrine and corticotropin-releasing hormone concentrations in post-traumatic stress disorder.
Geracioti TD; Baker DG; Kasckow JW; Strawn JR; Jeffrey Mulchahey J; Dashevsky BA; Horn PS; Ekhator NN
Psychoneuroendocrinology; 2008 May; 33(4):416-24. PubMed ID: 18295412
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid corticotropin-releasing factor and perceived early-life stress in depressed patients and healthy control subjects.
Carpenter LL; Tyrka AR; McDougle CJ; Malison RT; Owens MJ; Nemeroff CB; Price LH
Neuropsychopharmacology; 2004 Apr; 29(4):777-84. PubMed ID: 14702025
[TBL] [Abstract][Full Text] [Related]
14. Low cocaine- and amphetamine-regulated transcript (CART) peptide levels in human cerebrospinal fluid of major depressive disorder (MDD) patients.
Yoon HS; Hattori K; Sasayama D; Kunugi H
J Affect Disord; 2018 May; 232():134-138. PubMed ID: 29486339
[TBL] [Abstract][Full Text] [Related]
15. The change of insulin levels after six weeks antidepressant use in drug-naïve major depressive patients.
Chang HH; Chi MH; Lee IH; Tsai HC; Gean PW; Yang YK; Lu RB; Chen PS
J Affect Disord; 2013 Sep; 150(2):295-9. PubMed ID: 23664565
[TBL] [Abstract][Full Text] [Related]
16. Low cerebrospinal fluid corticotropin-releasing hormone concentrations in eucortisolemic depression.
Geracioti TD; Loosen PT; Orth DN
Biol Psychiatry; 1997 Aug; 42(3):165-74. PubMed ID: 9232208
[TBL] [Abstract][Full Text] [Related]
17. The recency ratio is associated with reduced CSF glutamate in late-life depression.
Bruno D; Nierenberg J; Cooper TB; Marmar CR; Zetterberg H; Blennow K; Hashimoto K; Pomara N
Neurobiol Learn Mem; 2017 May; 141():14-18. PubMed ID: 28323201
[TBL] [Abstract][Full Text] [Related]
18. Low cerebrospinal fluid glutamate and glycine in refractory affective disorder.
Frye MA; Tsai GE; Huggins T; Coyle JT; Post RM
Biol Psychiatry; 2007 Jan; 61(2):162-6. PubMed ID: 16735030
[TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal fluid immunoreactive corticotropin-releasing hormone and adrenocorticotropin secretion in Cushing's disease and major depression: potential clinical implications.
Kling MA; Roy A; Doran AR; Calabrese JR; Rubinow DR; Whitfield HJ; May C; Post RM; Chrousos GP; Gold PW
J Clin Endocrinol Metab; 1991 Feb; 72(2):260-71. PubMed ID: 1846869
[TBL] [Abstract][Full Text] [Related]
20. Corticotropin-releasing factor, interleukin-6, brain-derived neurotrophic factor, insulin-like growth factor-1, and substance P in the cerebrospinal fluid of civilians with posttraumatic stress disorder before and after treatment with paroxetine.
Bonne O; Gill JM; Luckenbaugh DA; Collins C; Owens MJ; Alesci S; Neumeister A; Yuan P; Kinkead B; Manji HK; Charney DS; Vythilingam M
J Clin Psychiatry; 2011 Aug; 72(8):1124-8. PubMed ID: 21208596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
